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Brief Report
Child and Adolescent Psychiatrists’ Attitudes
and Practices Prescribing Second Generation Antipsychotics
Angie Mae Rodday, MS,1,2 Susan K. Parsons, MD, MRP,1,2,3 Christoph U. Correll, MD,4
Adelaide S. Robb, MD,5 Bonnie T. Zima, MD,6 Tully S. Saunders, BS,1 and Laurel K. Leslie, MD, MPH1,2,3
Abstract
Objective: The purpose of this study was to examine psychiatrists’ attitudes and practices in prescribing second-generation
antipsychotics (SGA) to children and adolescents (referred to here as ‘‘children’’) and identify factors associated with off-
label SGA use.
Methods: A survey was mailed to a national, randomly selected sample of 1600 child and adolescent psychiatrists identified
by the American Medical Association. Multivariable logistic regression was used to identify factors, including psychiatrists’
characteristics, practice characteristics, and psychiatrists’ attitudes, that are associated with off-label SGA use (i.e., SGAs
used in children with attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder, or
nonbipolar mood disorders).
Results: The final sample included 340 psychiatrists. Overall, respondents reported higher use and appropriateness of SGAs
for United States Food and Drug Administration (FDA)-approved disorders, symptoms of aggression, and older child age.
More than one third (36%) of respondents reported some off-label SGA use. Significant predictors of off-label use were:
Practicing at inpatient/residential facilities (odds ratio [OR] = 4.2, p = 0.001); white/non-Hispanic race/ethnicity (OR= 0.3,
p < 0.0001), agreeing that SGAs should be used for ADHD with aggression (OR = 7.1, p < 0.0001); and agreeing that SGAs
should be used for severe delinquent behaviors (OR = 1.9, p = 0.03).
Conclusions: Psychiatrists’ attitudes about prescribing SGAs to children exhibiting aggressive symptoms were associated
with off-label SGA use. Research is needed to understand the construct of aggression, potential interaction effects of
aggression with diagnostic criteria, and their impact on SGA use.
Introduction
Research over the last decade indicates increasing use ofsecond-generation antipsychotics (SGA) among children and
adolescents (hereafter referred to as ‘‘children’’) (Olfson et al.
2012; Birnbaum et al. 2013). Increased use partially reflects a
growing evidence base and subsequent United States Food and
Drug Administration (FDA) approval for psychotic or manic
symptoms associated with schizophrenia and bipolar disorder and
for aggressive symptoms associated with autism spectrum dis-
orders (ASD) (Agency for Healthcare, Research and Quality
2010). There also has been increased off-label SGAs use among
children with attention-deficit/hyperactivity disorder (ADHD),
oppositional defiant disorder (ODD), conduct disorder (CD), and
nonbipolar mood disorders (Shekelle et al. 2007; Crystal et al.
2009), despite limited evidence of efficacy and documentation of
cardiometabolic side effects (Correll et al. 2010; Maayan and
Correll 2011).
Aggression occurs frequently in children with ADHD, ODD,
CD, and nonbipolar mood disorders, and is considered the leading
reason worldwide for psychotropic medication use in children
( Jensen et al. 2007). Although the construct of aggression is not
fully agreed upon, it is associated with a number of diagnoses. Early
research focused on physical aggression, whereas recent research
has highlighted symptoms of impulsive aggression (e.g., being
‘‘touchy’’, ‘‘oppositional’’) and other nonspecific behaviors (e.g.,
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‘‘explosive outbursts’’) that occur outside of expected social and
developmental contexts (Scotto Rosato et al. 2012).
We conducted a survey of child and adolescent psychiatrists to
examine attitudes and practices in prescribing SGAs. Specifically,
we looked at factors associated with off-label SGA use, including
psychiatrists’ characteristics, practice characteristics, and psychi-
atrists’ attitudes.
Methods
Using the American Medical Association’s (AMA) mailing list,
6156 child and adolescent psychiatrists were identified from which
1600 were randomly selected. Eligibility criteria were: 1) Providing
care for children 3–18 years of age, and 2) specializing in child and/
or adolescent psychiatry. Psychiatrists who were not based in the
United States, were retired, or were residents/fellows were ex-
cluded. Of 362 respondents (24%), 94% met eligibility criteria,
yielding a final sample of 340.
Data were collected using a survey developed by study inves-
tigators. Sections included 1) psychiatrist and practice setting
characteristics, 2) self-reported rate of prescribing SGAs by child
age and disorder, 3) appropriateness of SGA use by age and
symptoms, including aggression, and 4) attitudes toward SGAs and
behavioral interventions for aggression. The institutional review
board (IRB)-approved survey was mailed twice at 3 week intervals,
from February to March 2012.
Means, standard deviations (SD), frequencies, and percentages
were used to describe the sample, rate of SGA use ( > 50% versus
£ 50% of the time), appropriateness of SGA use (moderate/very
appropriate versus minimal/not appropriate), and attitudes toward
SGA use and behavioral interventions for aggression (moderately/
strongly agree versus moderately/strongly disagree). We used
logistic regression to estimate odds ratios (ORs) and 95% confi-
dence intervals (CI) of off-label SGA use (i.e., ADHD, ODD, CD,
or nonbipolar mood disorders). The following covariates were
tested in univariate analysis: Years in practice, respondent race/
ethnicity (white/non-Hispanic versus other), respondent gender,
board certification in child and adolescent psychiatry, population
density where respondent was based, practice setting (inpatient/
residential facility versus other), ‡ 50% versus < 50% of patients
with private insurance, and attitudes toward SGAs and behavioral
interventions for aggression. Covariates with p < 0.2 were consid-
ered in multivariable modeling; backwards selection eliminated
variables with p< 0.1. Multicollinearity was assessed using vari-
ance inflation factors (VIF). Alpha was set at 0.05 and tests were
two sided; SAS version 9.3 (Cary, NC) was used.
Results
Among the final sample of 340, slightly over half (55%, n = 185)
were male and 71% (n=236) were white/non-Hispanic. Respondents’
mean age was 53 years (SD=12) and mean years in practice was 18
(SD=11). The most common practice setting was private (42%,
n=139), then community mental health center (24%, n=80), aca-
demic medical center (16%, n=51), inpatient/residential facility
(12%, n=38), and other (6%, n=20). Respondents reported working
in urban (48%, n=157), suburban (41%, n=132), and rural settings
(11%, n=35). Approximately half (46%, n=140) reported that ‡50%
of their patients had private insurance.
Reported SGA use was high for FDA-approved indications and
increased with child age, reaching 73% for adolescents with
schizophrenia (Table 1). Nevertheless, 36% (n = 130) reported
some off-label SGA use. Respondents reported low off-label SGA
use for ADHD across all ages ( £ 4%). For ODD/CD (7–19%) and
Table 1. Reported SGA Use and Appropriateness of SGA Use by Age Group
Age 3–5 Age 6–12 Age 13–18
% (num/denom)c % (num/denom)c % (num/denom)c
Reported SGA use by disordersa
FDA-approved indications
Schizophrenia 16.3% (33/202) 47.2% (119/252) 72.7% (218/300)
Bipolar disorder 17.5% (44/252) 36.3% (114/314) 64.2% (210/327)
Autism spectrum disorders 17.1% (52/305) 30.8% (99/322) 40.0% (130/325)
Off-label uses
Mood disorders 11.3% (33/291) 16.7% (53/318) 24.7% (82/332)
Disruptive behavior disorders (CD, ODD) 7.3% (22/301) 11.9% (38/320) 18.5% (60/325)
ADHD/ADD 4.0% (12/300) 1.9% (6/319) 2.5% (8/326)
Appropriateness of SGA use by symptomsb
Target symptoms of disorders
Has auditory hallucinations 56.4% (186/330) 87.0% (288/331) 94.3% (315/334)
Has sudden mood changes 15.1% (50/331) 39.0% (130/333) 55.9% (186/333)
Acts as if ‘‘driven by a motor’’ 2.7% (9/332) 8.5% (28/331) 9.9% (33/333)
Aggressive symptoms
Physically harms or hurts self on purpose 35.4% (117/331) 49.3% (164/333) 59.0% (197/334)
Is explosive or easily angered 16.9% (56/331) 39.8% (132/332) 53.5% (177/331)
Has prolonged temper tantrums 15.8% (52/329) 32.9% (110/334) 50.0% (167/334)
Destroys property 19.1% (63/330) 31.3% (104/332) 40.0% (134/335)
Gets into fights without thinking 9.4% (31/329) 25.5% (85/333) 39.0% (130/333)
Threatens people verbally 8.2% (27/328) 22.6% (75/332) 32.4% (108/333)
aReported use includes prescribing SGAs > 50% of the time.
bAppropriateness includes both moderately and very appropriate.
cNumerator and denominator provided for each response as denominator varied by age (i.e., option to select ‘‘not seen in my practice’’).
SGA, second-generation antipsychotic; num, numerator; denom, denominator; CD, conduct disorder; ODD, oppositional defiant disorder; ADHD,
attention-deficit/hyperactivity disorder.
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nonbipolar mood disorders (11–25%), reported SGA use was also
lower, but increased with child age.
Respondents indicated the highest levels of appropriateness of
SGA use for symptoms related to schizophrenia (i.e., auditory
hallucinations, Table 1). For classic ADHD symptoms (i.e., ‘‘driven
by a motor’’) few respondents considered SGA use appropriate for
any age group (£10%). Conversely, relatively high proportions of
respondents considered SGA use appropriate for symptoms associ-
ated with physical and impulsive aggression.
Almost one fifth (19%, n= 64) agreed that SGAs were the best
initial medication treatment for children taking stimulants for
ADHD who exhibited aggressive symptoms, and 29% (n= 96)
agreed that SGAs were the best initial medication treatment for
children exhibiting severe delinquent behaviors (e.g., assault, de-
struction of property). In contrast, 68% (n = 226) agreed that SGAs
were the best initial medication treatment for children with ASD
exhibiting aggressive symptoms. Regarding behavioral interven-
tions, whereas 43% (n= 144) agreed that the majority of families
could implement the interventions to manage the child’s aggres-
sion, 40% (n= 133) agreed that there was difficulty accessing be-
havioral interventions for patients on psychotropic medications.
On multivariable logistic regression (Table 2), respondents
practicing at inpatient/residential facilities were more likely to re-
port off-label SGA use (OR = 4.2; 95% CI = 1.8, 10.2; p = 0.001).
Respondents were more likely to report off-label SGA use if they
agreed that SGAs were the best initial medication treatment for
children taking stimulants for ADHD who exhibited aggressive
symptoms (OR = 7.1; 95% CI= 3.4, 15.0; p< 0.0001) or agreed that
SGAs were the best initial medication treatment for children ex-
hibiting severe delinquent behaviors (OR = 1.9; 95% CI = 1.1, 3.6;
p = 0.03). White/non-Hispanic respondents were less likely to re-
port off-label SGA use (OR = 0.3; 95% CI= 0.2, 0.5; p< 0.0001).
There was no evidence of multicollinearity (VIFs < 1.2).
Discussion
Our results indicate that one third of psychiatrists reported off-label
SGA use. Findings suggest several explanatory factors. First, psy-
chiatrists providing care at inpatient/residential facilities predictably
used SGAs for off-label indications, likely reflecting increased se-
verity of illness in children treated in those facilities. Second, psy-
chiatrists who agreed that SGAs should be used for aggression with
ADHD and severe delinquent behaviors were more likely to report
off-label SGA use. Access to behavioral interventions and parental
ability to implement them were not included in the model based on
univariate analyses. We did not ascertain whether respondents tried
behavioral interventions prior to, or simultaneously with, SGAs.
Although the appropriateness of SGA use for different symp-
toms closely tracked associated disorders, aggressive symptoms
appeared to be strongly associated with SGA use. Interestingly,
psychiatrists reported similar levels of appropriateness for ag-
gression symptoms as for sudden mood changes. In the absence of a
Table 2. Univariate and Multivariable Logistic Regression for Off-Label SGA Use in Children and Adolescents
Univariate Multivariable
OR (95% CI) p value OR (95% CI) p value
Psychiatrist characteristics
Male 0.76 (0.48, 1.21) 0.25
Race/ethnicity
White/non-Hispanic 0.32 (0.20, 0.53) < 0.0001 0.28 (0.16, 0.51) < 0.0001
Other (reference)
Board certified in child and adolescent psychiatry 0.55 (0.32, 0.93) 0.03
Years in practice 0.97 (0.95, 0.99) 0.009 0.97 (0.94, 0.99) 0.009
Practice characteristics
Practice setting
Inpatient/residential facility 2.85 (1.31, 6.22) 0.009 4.24 (1.76, 10.18) 0.001
Other (reference)
Over 50% of patients have private insurance 0.70 (0.43, 1.13) 0.14
Population density
Urban (reference)
Suburban 0.81 (0.49, 1.34) 0.41
Rural 0.67 (0.30, 1.51) 0.33
Psychiatrist attitudes
SGAs best initial treatment for aggression in those
on stimulants for ADHDa
4.36 (2.42, 7.84) < 0.0001 7.08 (3.35, 14.99) < 0.0001
SGAs best initial treatment for aggression in those with ASDb 2.72 (1.56, 4.73) 0.0004
SGAs best initial treatment for those who exhibit severe
delinquent behaviorsc
2.61 (1.57, 4.33) 0.0002 1.94 (1.05, 3.59) 0.03
Difficult to access behavior interventions for patients
on psychotropic drugsd
1.21 (0.76, 1.93) 0.42
Majority of families can implement behavioral strategies
to manage aggressione
0.83 (0.52, 1.32) 0.43
aSGAs are the best initial medication treatment for children who exhibit aggressive symptoms who are already taking stimulants for ADHD.
bSGAs are the best initial medication treatment for children who exhibit aggressive symptoms and have an ASD.
cSGAs are the best initial medication treatment for children who exhibit severe delinquent behaviors (e.g., assault, destruction of property).
dIt is difficult to access behavioral interventions for the majority of my patients who are on psychotropic medication.
eThe majority of my patients’ families can implement behavioral strategies to manage their child’s aggression.
SGA, second-generation antipsychotic; ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder.
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strong evidence base, expert guidelines for the management of
aggression for children in inpatient and outpatient settings are
available to guide practice; however, it remains critical to conduct
ongoing comparative effectiveness studies of those guidelines
(Pappadopulos et al. 2003; Schur et al. 2003; Pappadopulos et al.
2011; Knapp et al. 2012; Scotto Rosato et al. 2012).
Limitations
This study has some limitations. The low response rate and in-
ability to compare respondents and nonrespondents limits gener-
alizability. However, our response rate parallels that of other
surveys conducted using the AMA mailing list (Needle et al. 2012)
and the gender and age distribution match those of other studies of
child and adolescent psychiatrists (Association of American
Medical Colleges: Center for Workforce Studies 2008). Given that
the survey was developed specifically for this study, some factors
that may explain SGA use, such as the additive or synergistic im-
pact of overlapping symptoms, were not assessed.
Clinical Significance
Psychiatrists’ attitudes about prescribing SGAs to children ex-
hibiting aggressive symptoms were associated with off-label SGA
use. Given that aggression is not associated with a single disorder,
further research is needed to understand the construct of aggression,
potential interaction effects of aggression with diagnostic criteria,
and their respective impact on SGA use.
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